In the cardiovascular system, histamine is released from mast cells, which are often located in coronary vessels and the myocardium; both mast cells and histamine have been implicated in CVD (4) . Histamine is one of the neurohormonal factors that activate various cellular functions by stimulating histamine receptors (5), and histamine H 2 receptors exist in the heart as well as gastric cells.
Because histamine H 2 receptors are coupled to G proteins, as well as the beta receptors (6), histamine provokes positive inotropic effects (1, 7) , and the blockage of histamine H 2 receptors decreases cardiac output (7) .
Increases in mast cells have been observed in the hearts of patients with cardiac hypertrophy, dilated and ischemic cardiomyopathy (8) , and myocardial infarction (9) . Furthermore, histamine is present in high concentrations in cardiac tissues in most animal species, including humans (6), and its release from cardiac stores and the subsequent actions on the heart may be important in the pathophysiology of CVD.
TRANSLATING BASIC RESEARCH TO CLINICAL MEDICINE
The study from Leary et al. (3) intriguingly reports that histamine H 2 receptor antagonists (H2RAs) prevent the onset of CHF in a cohort from the MESA study (Multi-Ethnic Study of Atherosclerosis). This is definitively demonstrated by a prospective, observational, and longitudinal study, which is very difficult to perform but provides better evidence than crosssectional or retrospective analyses like those used in our previous study (10) . The authors prospectively followed the residents of 6 U.S. communities for 10 years and observed the onset of CVD in normal subjects who did or did not use blockers of histamine H 2 receptors. In our previous paper (10), we reported that blockers of histamine H 2 receptors are effective for CHF patients in a retrospective cohort study and a prospective randomized study. These 2 studies (i.e., the present study and ours) appear to be similar, but that is not the case because prevention is the action undertaken before the onset of events and treatment is undertaken after event onset. This is the novel point in the present study: onset of CHF is classified as to ischemic and nonischemic causes; the former includes coronary artery disease, and the latter includes hypertensive heart disease and diabetic cardiomyopathy. H2RA users between clinical medicine and basic research (17) .
P U B L I S H E D B Y E L S E V I E R h t t p :

STRENGTHS AND LIMITATIONS
There are many strengths of the present study (3), the first being that whereas a prevention study is difficult to conduct because the researchers must enroll many subjects to obtain clinical outcomes, a treatment trial is rather easy because cardiovascular events occur more frequently than in a prevention study. Secondly, as a multicenter trial, this study was more comprehensive than a single-center trial.
Lastly, the authors employed multiple ethnic groups, which increased the feasibility of the present results. 
